C. Collins James's most recent trade in Archer Daniels Midland Co. was a trade of 885 Stock Units done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 885 | 11,438 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 90 | 10,552 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 852 | 10,462 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2025 | 79 | 9,610 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 978 | 9,530 | - | - | Stock Units | |
| Senti Biosciences Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 21,950 | 21,950 | - | - | Stock Option (Right to Buy) | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 88 | 8,552 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 1,065 | 8,463 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 75 | 7,398 | - | - | Stock Units | |
| Senti Biosciences Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 43,900 | 43,900 | - | - | Stock Option (Right to Buy) | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 1,020 | 7,322 | - | - | Stock Units | |
| Archer-Daniels-Midland | Collins C. James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 59 | 6,302 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 857 | 6,243 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2024 | 45 | 5,386 | - | - | Stock Units | |
| Senti Biosciences Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2024 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 846 | 5,341 | - | - | Stock Units | |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 36 | 4,495 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 793 | 4,458 | - | - | Stock Units | |
| Archer-Daniels-Midland | James Collins C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 34 | 3,665 | - | - | Stock Units | |
| Archer-Daniels-Midland | C. James Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 693 | 3,631 | - | - | Stock Units | |
| Archer-Daniels-Midland | C. Collins James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 17 | 2,937 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2023 | 661 | 2,920 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 13 | 2,258 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 667 | 2,245 | - | - | Stock Units | |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Senti Biosciences Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 9 | 1,578 | - | - | Stock Units | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 27 Apr 2023 | 1,000 | 125,288 (0%) | 0% | 11.5 | 11,490 | Common Stock | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 626 | 1,569 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 5 | 942 | - | - | Stock Units | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 31 Jan 2023 | 3,000 | 124,288 (0%) | 0% | 0 | Common Stock | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 17 Jan 2023 | 1,000 | 0 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 17 Jan 2023 | 1,000 | 121,288 (0%) | 0% | 9.0 | 9,030 | Common Stock | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 540 | 937 | - | - | Stock Units | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2022 | 1 | 397 | - | - | Stock Units | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 9,000 | 108,288 (0%) | 0% | 9.0 | 81,270 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 9,000 | 1,000 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 4,000 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 4,000 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 120,288 (0%) | 0% | 10.9 | 65,520 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 114,288 (0%) | 0% | 10.8 | 64,860 | Common Stock | |
| Archer-Daniels-Midland | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 395 | 395 | - | - | Stock Units | |
| Senti Biosciences Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 12 Jan 2022 | 3,000 | 99,288 (0%) | 0% | 0 | Common Stock | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Sep 2021 | 500 | 96,288 (0%) | 0% | 8.9 | 4,465 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Sep 2021 | 500 | 0 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 19 Aug 2021 | 4,000 | 95,788 (0%) | 0% | 8.9 | 35,720 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 19 Aug 2021 | 4,000 | 500 | - | - | Stock Options | ||
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 165,563 | 331,126 | - | - | Non-Qualified Stock Options | |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.22 per share. | 10 Aug 2021 | 165,563 | 491,590 (0%) | 0% | 31.2 | 5,168,877 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 113,777 | 377,813 (0%) | 0% | 45.4 | 5,168,889 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.94 per share. | 10 Aug 2021 | 75,463 | 398,357 (0%) | 0% | 41.9 | 3,164,918 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 75,463 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 69,666 | 328,691 (0%) | 0% | 45.4 | 3,164,926 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 23,796 | 354,017 (0%) | 0% | 45.4 | 1,081,052 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 2,664 | 326,027 (0%) | 0% | 45.4 | 121,026 | Common Stock |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 131,943 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.68 per share. | 18 May 2021 | 131,943 | 436,781 (0%) | 0% | 34.7 | 4,575,783 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.00 per share. | 18 May 2021 | 99,486 | 337,295 (0%) | 0% | 46.0 | 4,575,859 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.76 per share. | 18 May 2021 | 82,464 | 368,664 (0%) | 0% | 26.8 | 2,206,737 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 82,464 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 47,979 | 320,685 (0%) | 0% | 46.0 | 2,206,794 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 27,837 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.36 per share. | 18 May 2021 | 27,837 | 309,577 (0%) | 0% | 32.4 | 900,805 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 19,585 | 289,992 (0%) | 0% | 46.0 | 900,812 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.00 per share. | 18 May 2021 | 15,847 | 304,838 (0%) | 0% | 46.0 | 728,883 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 14,915 | 322,380 (0%) | 0% | 46.0 | 686,015 | Common Stock |
| Corteva | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 3,792 | 286,200 (0%) | 0% | 46.0 | 174,413 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 31.83 per share. | 05 Apr 2021 | 953 | 13,754 (0%) | 0% | 31.8 | 30,332 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.02 per share. | 02 Apr 2021 | 380 | 14,707 (0%) | 0% | 32.0 | 12,168 | Common Stock |